Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Other developed nations | Clear Filter
Summary:A letter from The White House, dated July 31, 2025, to Pfizer CEO Albert Bourla, outlines an Executive Order signed on May 12, 2025, aimed at ending high drug prices in the United States by mandating Most-Favored-Nation pricing for all drugs for American patients, and warns of consequences if drug manufacturers do not comply within 60 days.
Sentiment:Authoritative Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to implement Most-Favored-Nation (MFN) drug pricing for American patients.
- American drug prices are up to three times higher than in other developed nations due to 'global freeloading'.
- The Administration demands Pfizer and all drug manufacturers extend MFN pricing to Medicaid patients for existing drugs.
- The Administration demands Pfizer and all drug manufacturers guarantee MFN pricing for newly-launched drugs for all payers.
- The Administration demands increased revenues from abroad be repatriated to lower US drug prices.
- The Administration demands participation in direct purchasing models at MFN pricing.
- Non-compliance will result in the deployment of 'every tool in our arsenal' to protect American families.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:5/10
« Previous
Page 1 of 1
Next »